Udit Batra, PhD has been named Waters’ new president and CEO, effective September 1, 2020.
Waters Corporation announced on July 15, 2020 that Udit Batra, PhD has been named Waters’ new president and CEO, effective September 1, 2020. He will work alongside the company’s current president and CEO, Christopher O’Connell, who will remain in his role until Batra’s September start date.
Batra previously served as president and CEO of the global Consumer Health business of Merck KGaA in Darmstadt, Germany, and most recently held the role of CEO of Merck KGaA’s Life Science business, according to a company press release. There, he headed the business’ integration of Sigma-Aldrich, which resulted in the creation of MilliporeSigma, Merck KGaA’s United States and Canada identity.
“We are pleased to have identified such an accomplished and experienced candidate and are confident that Udit is the right leader to take Waters to the next level,” said Dr. Flemming Ornskov, chairman of the board at Waters, in the press release. “His focus on commercial execution and innovation, proven ability to build strong and collaborative cultures, and intense commitment to serving customers have translated into tangible results. Building on Waters’ strong foundation, we look forward to the company’s next phase of innovation and growth with Udit at the helm. We are grateful for the continued hard work and leadership of Chris and the entire Waters team to remain focused on our business, continue our progress, and ensure a seamless transition.”
“Throughout my career, I have focused on starting with listening and learning, embracing challenges, and working with talented people,” Batra added in the press release. “I join Waters with energy and a shared passion for technology development and serving our customers to drive value for shareholders while making the world a better place.”
Source: Waters
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.